Share on StockTwits
 

Bristol-Myers Squibb (NYSE:BMY) Director Lewis B. Campbell unloaded 2,500 shares of Bristol-Myers Squibb stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $48.28, for a total value of $120,700.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Bristol-Myers Squibb (NYSE:BMY) traded down 0.82% on Wednesday, hitting $48.54. The stock had a trading volume of 12,446,709 shares. Bristol-Myers Squibb has a 52-week low of $36.03 and a 52-week high of $56.83. The stock has a 50-day moving average of $52.96 and a 200-day moving average of $48.59. The company has a market cap of $79.923 billion and a price-to-earnings ratio of 31.78.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Friday, January 24th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.10. The company had revenue of $4.44 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter last year, the company posted $0.47 earnings per share. Bristol-Myers Squibb’s revenue was up 6.0% compared to the same quarter last year. Analysts expect that Bristol-Myers Squibb will post $1.77 EPS for the current fiscal year.

A number of research firms have recently commented on BMY. Analysts at TheStreet reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research note to investors on Tuesday. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Bristol-Myers Squibb in a research note to investors on Monday, January 27th. They now have a $53.00 price target on the stock. Finally, analysts at Argus raised their price target on shares of Bristol-Myers Squibb from $58.00 to $62.00 in a research note to investors on Wednesday, January 15th. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Bristol-Myers Squibb currently has a consensus rating of “Buy” and an average target price of $53.36.

Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.